State Street Corp ownership in 8AP / Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

DE ˙ DB ˙ US00847X1046

23,40 € ↑0,80 (3,54%)

2026-06-04
AKTIENPREIS

Security	DE:8AP / Agios Pharmaceuticals, Inc.
Institution	State Street Corp
Latest Disclosed Ownership	3,108,145 shares
Ownership	5.30%

2026-02-09 - State Street Corp has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,108,145 shares of Agios Pharmaceuticals, Inc. (DE:8AP). This represents 5.3 percent ownership of the company. In their previous filing dated 2024-01-22 , State Street Corp had reported owning 2,625,685 shares, indicating an increase of 18.37 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2026-02-09	2026-02-09	13G	2,625,685	3,108,145	18.37	5.30	12.77
2024-01-22	2024-01-22	13G/A	3,179,068	2,625,685	-17.41	4.70	-18.83
2023-02-08	2023-02-08	13G/A	2,992,882	3,179,068	6.22	5.79	5.08
2022-02-09	2022-02-09	13G		2,992,882		5.51

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-15	2026-03-31	13F	AGIOS PHARMACEUTICALS	COM	00847X104	3,364,879	256,734	8.26	113,719	34.41	0.0039
2026-02-13	2025-12-31	13F	AGIOS PHARMACEUTICALS	COM	00847X104	3,108,145	845,433	37.36	84,604	-6.85	0.0028
2025-11-14	2025-09-30	13F	AGIOS PHARMACEUTICALS	COM	00847X104	2,262,712	311,599	15.97	90,825	39.96	0.0031
2025-08-14	2025-06-30	13F	AGIOS PHARMACEUTICALS	COM	00847X104	1,951,113	-498,366	-20.35	64,894	-9.58	0.0024
2025-05-15	2025-03-31	13F	AGIOS PHARMACEUTICALS	COM	00847X104	2,449,479	297,202	13.81	71,770	1.48	0.0030
2025-02-14	2024-12-31	13F	AGIOS PHARMACEUTICALS	COM	00847X104	2,152,277	-179,156	-7.68	70,724	-31.72	0.0028
2024-11-14	2024-09-30	13F	AGIOS PHARMACEUTICALS	COM	00847X104	2,331,433	216,484	10.24	103,586	13.59	0.0042
2024-08-14	2024-06-30	13F	AGIOS PHARMACEUTICALS	COM	00847X104	2,114,949	-1,023,248	-32.61	91,197	-0.61	0.0040
2024-05-15	2024-03-31	13F	AGIOS PHARMACEUTICALS	COM	00847X104	3,138,197	512,512	19.52	91,761	56.92	0.0041
2024-02-14	2023-12-31	13F	AGIOS PHARMACEUTICALS	COM	00847X104	2,625,685	361,851	15.98	58,474	4.36	0.0028
2023-11-14	2023-09-30	13F	AGIOS PHARMACEUTICALS	COM	00847X104	2,263,834	-317,635	-12.30	56,030	-23.36	0.0031
2023-08-14	2023-06-30	13F	AGIOS PHARMACEUTICALS	COM	00847X104	2,581,469	-482,533	-15.75	73,107	3.87	0.0038
2023-05-15	2023-03-31	13F	AGIOS PHARMACEUTICALS	COM	00847X104	3,064,002	-115,066	-3.62	70,380	-21.16	0.0040
2023-05-15	2022-12-31	13F/A-99	AGIOS PHARMACEUTICALS	COM	00847X104	3,179,068	544,296	20.66	89,268	19.81	0.0052
2023-05-15	2022-12-31	13F	AGIOS PHARMACEUTICALS	COM	00847X104	3,179,068	544,296		89,268		0.0052
2022-11-15	2022-09-30	13F	AGIOS PHARMACEUTICALS	COM	00847X104	2,634,772	-766,447	-22.53	74,511	-1.19	0.0047
2022-08-15	2022-06-30	13F	AGIOS PHARMACEUTICALS	COM	00847X104	3,401,219	214,706	6.74	75,405	-18.71	0.0045
2022-05-16	2022-03-31	13F	AGIOS PHARMACEUTICALS	COM	00847X104	3,186,513	193,631	6.47	92,759	-5.71	0.0046
2022-02-14	2021-12-31	13F	AGIOS PHARMACEUTICALS	COM	00847X104	2,992,882	599,992	25.07	98,376	-10.92	0.0047
2021-11-15	2021-09-30	13F	AGIOS PHARMACEUTICALS	COM	00847X104	2,392,890	422,831	21.46	110,432	1.72	0.0058
2021-08-16	2021-06-30	13F	AGIOS PHARMACEUTICALS	COM	00847X104	1,970,059	237,469	13.71	108,570	21.35	0.0057
2021-07-09	2021-03-31	13F/A-1	AGIOS PHARMACEUTICALS	COM	00847X104	1,732,590	-889,691	-33.93	89,471	-21.26	0.0051
2021-05-17	2021-03-31	13F	AGIOS PHARMACEUTICALS	COM	00847X104	1,732,590	-889,691		89,471		0.0051
2021-02-16	2020-12-31	13F	AGIOS PHARMACEUTICALS	COM	00847X104	2,622,281	555,259	26.86	113,623	57.05	0.0070
2020-11-10	2020-09-30	13F	AGIOS PHARMACEUTICALS	COM	00847X104	2,067,022	172,394	9.10	72,346	-28.60	0.0049
2020-08-14	2020-06-30	13F	AGIOS PHARMACEUTICALS	COM	00847X104	1,894,628	-14,681	-0.77	101,325	49.57	0.0074
2020-06-19	2020-03-31	13F/A-1	AGIOS PHARMACEUTICALS	COM	00847X104	1,909,309	24,523	1.30	67,742	-24.73	0.0059
2020-05-11	2020-03-31	13F	AGIOS PHARMACEUTICALS	COM	00847X104	1,909,309	24,523		67,742		5,949.1116
2020-02-06	2019-12-31	13F	AGIOS PHARMACEUTICALS	COM	00847X104	1,884,786	33,449	1.81	89,999	50.04	0.0062
2019-11-14	2019-09-30	13F	AGIOS PHARMACEUTICALS	COM	00847X104	1,851,337	104,222	5.97	59,983	-31.17	0.0045
2019-08-14	2019-06-30	13F	AGIOS PHARMACEUTICALS	COM	00847X104	1,747,115	157,544	9.91	87,146	-18.71	0.0065
2019-05-15	2019-03-31	13F	AGIOS PHARMACEUTICALS	COM	00847X104	1,589,571	-56,357	-3.42	107,201	41.25	0.0084
2019-02-12	2018-12-31	13F	AGIOS PHARMACEUTICALS	COM	00847X104	1,645,928	83,947	5.37	75,894	-37.00	0.0069
2018-11-09	2018-09-30	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	1,561,981	213,465	15.83	120,460	6.05	0.0093
2018-08-14	2018-06-30	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	1,348,516	-140,992	-9.47	113,587	-6.75	0.0095
2018-05-15	2018-03-31	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	1,489,508	146,869	10.94	121,814	58.72	0.0103
2018-02-14	2017-12-31	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	1,342,639	86,918	6.92	76,750	-8.43	0.0062
2017-11-14	2017-09-30	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	1,255,721	-47,245	-3.63	83,816	25.03	0.0072
2017-08-14	2017-06-30	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	1,302,966	97,220	8.06	67,036	-4.80	0.0059
2017-05-15	2017-03-31	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	1,205,746	-34,839	-2.81	70,417	36.01	0.0063
2017-02-09	2016-12-31	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	1,240,585	150,244	13.78	51,772	-10.11	0.0049
2017-01-13	2016-09-30	13F/A-1	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	1,090,341	191,155	21.26	57,594	52.88	0.0058
2016-11-14	2016-09-30	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	1,090,341			57,594
2016-08-12	2016-06-30	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	899,186	-204,476	-18.53	37,672	-15.92	0.0040
2016-05-20	2016-03-31	13F/A-1	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	1,103,662	200,468	22.20	44,803	-23.58	0.0048
2016-05-12	2016-03-31	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	1,103,662			44,803
2016-02-16	2015-12-31	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	903,194	320,847	55.10	58,631	42.64	0.0064
2015-11-16	2015-09-30	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	582,347	108,466	22.89	41,105	-21.95	0.0048
2015-08-13	2015-06-30	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	473,881	27,118	6.07	52,663	25.00	0.0056
2015-05-15	2015-03-31	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	446,763	73,380	19.65	42,131	0.72	0.0043
2015-02-11	2014-12-31	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	373,383	-170,801	-31.39	41,830	25.30	0.0042
2014-11-12	2014-09-30	13F/A-1	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	544,184	370,286	212.93	33,385	318.83	0.0036
2014-11-10	2014-09-30	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	544,184			33,385
2014-08-12	2014-06-30	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	173,898	85,117	95.87	7,971	129.32	0.0009
2014-05-15	2014-03-31	13F/A-1	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	88,781	6,760	8.24	3,476	76.99	0.0004
2014-05-13	2014-03-31	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	88,781			3,476
2014-02-06	2013-12-31	13F/A-1	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	82,021	25,321	44.66	1,964	23.91	0.0002
2013-11-12	2013-09-30	13F	AGIOS PHARMACEUTICALS	Common equity shares	00847X104	56,700	56,700		1,585		0.0002

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.